Dr. Matthew During, Ohio State University Professor of Molecular Virology, Immunology and Medical Genetics, Neuroscience and Neurosurgery, also serves as a Visiting Professor of Transitional Neuroscience at Oxford University in the United Kingdom. Since 1990, Dr. Matthew During has received numerous faculty appointments at highly respected institutions, including Yale University School of Medicine, the University of Auckland School of Medicine, Jefferson Medical College, and Cornell University’s Weill Medical College.Dr. Matthew During also brings over 20 years of research, administration, and clinical experience to each of his commercial endeavors. He was the original founder of Neurologix, Inc., a biotech company dedicated to the development and commercialization of gene transfer therapies for brain and central nervous system disorders, including epilepsy, Parkinson's disease, Huntington's disease, and depression. In 2012, Dr. During founded Obgenex, Inc., a biopharmaceutical company focused on treatments for metabolic syndrome, obesity, and diabetes.Dr. During continues to make significant and pioneering contributions to molecular biology and neuroscience, including a recent discovery concerning the effect of an active social life on the brain, and the brain, in turn, on stemming the proliferation of cancers and on burning rather than storing fat. With a significant number of scientific milestones under his belt, Dr. Matthew During has shared his research and findings in more than 200 scientific articles published in an array of peer-reviewed journals such as Nature, Science, Cell, Nature Medicine, Nature Genetics, Cell Metabolism, and Neuron. Dr. During also co-edited two books on gene therapy and contributed chapters to 17 medical titles. Because of his pioneering research and treatment methodologies, he has 40 patent and patent applications.